Loss of Dopamine Transporters in Methamphetamine Abusers Recovers with Protracted Abstinence
Top Cited Papers
- 1 December 2001
- journal article
- clinical trial
- Published by Society for Neuroscience in Journal of Neuroscience
- Vol. 21 (23), 9414-9418
- https://doi.org/10.1523/jneurosci.21-23-09414.2001
Abstract
Methamphetamine is a popular drug of abuse that is neurotoxic to dopamine (DA) terminals when administered to laboratory animals. Studies in methamphetamine abusers have also documented significant loss of DA transporters (used as markers of the DA terminal) that are associated with slower motor function and decreased memory. The extent to which the loss of DA transporters predisposes methamphetamine abusers to neurodegenerative disorders such as Parkinsonism is unclear and may depend in part on the degree of recovery. Here we assessed the effects of protracted abstinence on the loss of DA transporters in striatum, in methamphetamine abusers using positron emission tomography and [11C]d-threo-methylphenidate (DA transporter radioligand). Brain DA transporters in five methamphetamine abusers evaluated during short abstinence (<6 months) and then retested during protracted abstinence (12–17 months) showed significant increases with protracted abstinence (caudate, +19%; putamen, +16%). Although performance in some of the tests for which we observed an association with DA transporters showed some improvement, this effect was not significant. The DA transporter increases with abstinence could indicate that methamphetamine-induced DA transporter loss reflects temporary adaptive changes (i.e., downregulation), that the loss reflects DA terminal damage but that terminals can recover, or that remaining viable terminals increase synaptic arborization. Because neuropsychological tests did not improve to the same extent, this suggests that the increase of the DA transporters was not sufficient for complete function recovery. These findings have treatment implications because they suggest that protracted abstinence may reverse some of methamphetamine-induced alterations in brain DA terminals.This publication has 27 references indexed in Scilit:
- Association of Dopamine Transporter Reduction With Psychomotor Impairment in Methamphetamine AbusersAmerican Journal of Psychiatry, 2001
- Striatal dopamine nerve terminal markers in human, chronic methamphetamine usersNature Medicine, 1996
- Effects of Blood Flow on [11C]Raclopride Binding in the Brain: Model Simulations and Kinetic Analysis of PET DataJournal of Cerebral Blood Flow & Metabolism, 1994
- Single photon emission computed tomographic imaging demonstrates loss of striatal dopamine transporters in Parkinson disease.Proceedings of the National Academy of Sciences of the United States of America, 1993
- Positron emission tomographic imaging of the dopamine transporter with 11C‐WIN 35,428 reveals marked declines in mild Parkinson's diseaseAnnals of Neurology, 1993
- Neurotoxic Amphetamine Analogues: Effects in Monkeys and Implications for HumansaAnnals of the New York Academy of Sciences, 1992
- Quantitation of the human basal ganglia with positron emission tomography: a phantom study of the effect of contrast and axial positioningIEEE Transactions on Medical Imaging, 1991
- Graphical Analysis of Reversible Radioligand Binding from Time—Activity Measurements Applied to [N-11C-Methyl]-(−)-Cocaine PET Studies in Human SubjectsJournal of Cerebral Blood Flow & Metabolism, 1990
- Long-term effects of chronic methamphetamine administration in rhesus monkeysBrain Research, 1989
- Methamphetamine-induced depression of tryptophan hydroxylase: Recovery following acute treatmentEuropean Journal of Pharmacology, 1981